Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Vincerx Pharma, Inc. (VINC : NSDQ)
 
 • Company Description   
Vincerx Pharma Inc. is a biopharmaceutical company. It focuses on unmet medical needs of patients with cancer through paradigm-shifting therapeutics. Vincerx Pharma Inc. is based in PALO ALTO, Calif.

Number of Employees: 56

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.77 Daily Weekly Monthly
20 Day Moving Average: 78,261 shares
Shares Outstanding: 21.06 (millions)
Market Capitalization: $37.27 (millions)
Beta: 1.62
52 Week High: $18.43
52 Week Low: $1.67
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -31.40% -22.73%
12 Week -68.22% -65.06%
Year To Date -82.63% -78.78%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
260 SHERIDAN AVENUE SUITE 400
-
PALO ALTO,CA 94306
USA
ph: 650-800-6676
fax: -
None http://www.vincerx.com
 
 • General Corporate Information   
Officers
Ahmed M. Hamdy - Chief Executive Officer and Chairman
Alexander A. Seelenberger - Chief Financial Officer
Laura I. Bushnell - Director
Brian J. Druker - Director
John H. Lee - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 92731L106
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 21.06
Most Recent Split Date: (:1)
Beta: 1.62
Market Capitalization: $37.27 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.07 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.17 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.42
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -71.74%
vs. Previous Quarter: 7.06%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -59.83
12/31/21 - -58.98
09/30/21 - -76.19
ROA
03/31/22 - -48.95
12/31/21 - -44.37
09/30/21 - -49.75
Current Ratio
03/31/22 - 8.51
12/31/21 - 8.04
09/30/21 - 4.90
Quick Ratio
03/31/22 - 8.51
12/31/21 - 8.04
09/30/21 - 4.90
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 4.23
12/31/21 - 4.76
09/30/21 - 4.79
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©